Byron C. Scott, M.D.

Byron Scott
Byron C. Scott, M.D.

Byron C. Scott has served as a member of our Board since February 2021.  Dr. Scott has served as the Chief Operating Officer at Direct Relief, a humanitarian medical aid and disaster relief organization, since January 2024, where he was previously on the Board of Directors.  Dr. Scott has served as Adjunct Faculty at the University of Massachusetts, Amherst, Isenberg School of Management since 2016 and Adjunct Faculty at Thomas Jefferson University, Jefferson College of Population Health since 2019 where he teaches healthcare quality, patient safety, and performance improvement.  Dr. Scott served as Deputy Chief Health Officer at IBM Watson Health from 2017 to 2020, where he served as a consultant helping healthcare organizations align strategies and improve performance, along with supporting sales, marketing, and thought leadership.  Dr. Scott served at Truven Health Analytics, which was acquired by IBM in 2016, from 2014 to 2017, most recently as Associate Chief Medical Officer from 2015 to 2017.  Dr. Scott previously served at EmCare, a hospital-based physician practice management company that was part of Envision Healthcare, from 1995 to 2013, where he held positions of increasing responsibility, including most recently as Executive Vice President of the West Division from 2011 to 2013.

Dr. Scott is board certified in emergency medicine and previously practiced medicine for over 25 years. He serves as a member of the Board of Directors of Providence Health Plan and serves as a Board Trustee at Rady Children’s Hospital-San Diego.  Dr. Scott holds a B.S. in Psychobiology from the University of California, Los Angeles, a M.D. from the University of California, San Diego, and a M.B.A. from the University of Massachusetts, Amherst, Isenberg School of Management.  He is Directorship Certified by the National Association for Corporate Directors (NACD) and holds a CERT Cybersecurity Oversight Certification issued by Carnegie Mellon University and NACD.

 

Class II Director, Term Expires 2026

Independent Director